CN113613669A - 用于治疗哮喘的脂质运载蛋白突变蛋白 - Google Patents

用于治疗哮喘的脂质运载蛋白突变蛋白 Download PDF

Info

Publication number
CN113613669A
CN113613669A CN202080023518.0A CN202080023518A CN113613669A CN 113613669 A CN113613669 A CN 113613669A CN 202080023518 A CN202080023518 A CN 202080023518A CN 113613669 A CN113613669 A CN 113613669A
Authority
CN
China
Prior art keywords
fragment
variant
lipocalin mutein
subject
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080023518.0A
Other languages
English (en)
Chinese (zh)
Inventor
L·T·阿克塞尔松
D·R·克洛斯
P·加德纳
A·I·A·约夏尼恩
E·帕达尔
M·菲茨杰拉德
G·马奇纳
I·布伦斯
G·M·奥尔松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN113613669A publication Critical patent/CN113613669A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Otolaryngology (AREA)
  • Cell Biology (AREA)
CN202080023518.0A 2019-03-29 2020-03-25 用于治疗哮喘的脂质运载蛋白突变蛋白 Pending CN113613669A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962826791P 2019-03-29 2019-03-29
US62/826791 2019-03-29
US201962845774P 2019-05-09 2019-05-09
US62/845774 2019-05-09
US201962906443P 2019-09-26 2019-09-26
US62/906443 2019-09-26
PCT/EP2020/058360 WO2020200960A1 (en) 2019-03-29 2020-03-25 Lipocalin mutein for treatment of asthma

Publications (1)

Publication Number Publication Date
CN113613669A true CN113613669A (zh) 2021-11-05

Family

ID=70008540

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080023518.0A Pending CN113613669A (zh) 2019-03-29 2020-03-25 用于治疗哮喘的脂质运载蛋白突变蛋白

Country Status (11)

Country Link
US (1) US20220193191A1 (https=)
EP (1) EP3946415A1 (https=)
JP (1) JP2022526524A (https=)
KR (1) KR20210146934A (https=)
CN (1) CN113613669A (https=)
AU (1) AU2020252050A1 (https=)
CA (1) CA3133422A1 (https=)
IL (1) IL286756A (https=)
MA (1) MA55490A (https=)
SG (1) SG11202109839YA (https=)
WO (1) WO2020200960A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114780621A (zh) * 2022-06-23 2022-07-22 中铁电气化勘测设计研究院有限公司 一种轨道交通接触网缺陷检索方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020253034A1 (en) * 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
KR20230121785A (ko) 2020-12-18 2023-08-21 아스트라제네카 에이비이 천식 치료용 리포칼린 뮤테인 건조 분말 제형
WO2023143351A1 (zh) 2022-01-29 2023-08-03 上海盛迪医药有限公司 糖皮质激素的药物偶联物
WO2025026216A1 (zh) 2023-07-28 2025-02-06 江苏恒瑞医药股份有限公司 一种含有糖皮质激素的抗体药物偶联物的药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103998053A (zh) * 2011-12-13 2014-08-20 皮里斯股份公司 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
US8313924B2 (en) 2006-08-01 2012-11-20 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
RU2569745C2 (ru) * 2010-06-08 2015-11-27 Пиерис АГ Мутеины липокалина слезы, связывающие альфа il-4 r

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103998053A (zh) * 2011-12-13 2014-08-20 皮里斯股份公司 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G. MATSCHINER等: "Discovery and Development of AZD1402/PRS-060 a Potent and Selective Blocker of the IL-4 Receptor alpha", AMERICAN THORACIC SOCIETY INTERNATIONAL CONFERENCE ABSTRACTS, A34. ASTHMA CLINICAL STUDIES I, pages 1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114780621A (zh) * 2022-06-23 2022-07-22 中铁电气化勘测设计研究院有限公司 一种轨道交通接触网缺陷检索方法

Also Published As

Publication number Publication date
EP3946415A1 (en) 2022-02-09
AU2020252050A1 (en) 2021-11-11
IL286756A (en) 2021-10-31
JP2022526524A (ja) 2022-05-25
WO2020200960A1 (en) 2020-10-08
SG11202109839YA (en) 2021-10-28
US20220193191A1 (en) 2022-06-23
MA55490A (fr) 2022-02-09
KR20210146934A (ko) 2021-12-06
CA3133422A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
CN113613669A (zh) 用于治疗哮喘的脂质运载蛋白突变蛋白
Gibson et al. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8
EP2627673B1 (en) Therapies for improving pulmonary function
US8410049B2 (en) Methods and kits for preventing hypoglycemia
CN107073114B (zh) 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘
US20140378394A1 (en) Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
KR20160042123A (ko) 벤랄리주맙을 이용하여 천식 증상을 개선시키는 방법
Phipps et al. Anti-IL-5 (mepolizumab) reduces the expression of tenascin, procollagen III and lumican in the reticular basement membrane of human atopic asthmatics
RU2840902C2 (ru) Способы нормализации симптомов астмы с применением бенрализумаба
TW202241490A (zh) 用於治療氣喘之脂質運載蛋白突變蛋白乾粉配製物
KR20240033039A (ko) 호흡기 질환의 치료
Petraitytė Utilization and costs of drugs for asthma and chronic obstructive pulmonary disease treatment in Lithuania on 2006-2009 year
KR20130110225A (ko) 인터페론을 사용하여 폐질환을 치료하는 방법
Mishra et al. Intratracheal interleukin-13 induces eosinophilic esophagitis (EE)
Mason American Thoracic Society 2019 International Conference. Dallas, Texas, USA-May 17-22, 2019
Elsner et al. CRIC3, a chemokine receptor inactivator as a novel approach in the treatment of allergic diseases
HK1188603A (en) Therapies for improving pulmonary function
HK1188603B (en) Therapies for improving pulmonary function
HK1240824A1 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
HK1240824B (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
KR20080093016A (ko) 인터페론을 사용하여 폐질환을 치료하는 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211105

WD01 Invention patent application deemed withdrawn after publication